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Alterations in global DNA methylation and hydroxymethylation are not detected in
Alzheimer’s disease
Aims: Genetic factors do not seem to account fully for
Alzheimer disease (AD) pathogenesis. There is evidence for
the contribution of environmental factors, whose effect
may be mediated by epigenetic mechanisms. Epigenetics
involves the regulation of gene expression independently
of DNA sequence and these epigenetic changes are influ-
enced by age and environmental factors, with DNA
methylation being one of the best characterized epigenetic
mechanisms. The human genome is predominantly
methylated on CpG motifs, which results in gene silencing;
however methylation within the body of the gene may
mark active transcription. There is evidence suggesting an
involvement of environmental factors in the pathogenesis
of Alzheimer’s disease (AD), which prompted our study
examining DNA methylation in this disorder. Methods:
Using immunohistochemistry with 5-methylcytosine/5-
hydroxymethylcytosine antibodies we studied, in compari-
son with age matched controls, DNA methylation in
sporadic and familial AD cases in the entorhinal
cortex that exhibits substantial pathology and the cerebel-
lum, which is relatively spared. Results: Neuronal
nuclear labelling with 5-methylcytosine (5mC) and 5-
hydroxymethylcytosine (5hmC) was evident in all cases
studied. We did not detect any significant change in the
levels of nuclear staining in the AD samples compared
to neurologically normal controls. In the entorhinal
cortex we also examined global DNA methylation and
hydroxymethylation using an enzyme-linked immuno-
sorbent assay (ELISA). Conclusion: No significant differ-
ences were found between AD and control cases in global
levels of 5mC and 5hmC in the entorhinal cortex using
immunohistochemistry and enzyme-linked immunosorb-
ent assays.
Keywords: Alzheimer’s disease, epigenetics, hydroxymethylation, methylation
Introduction
Epigenetics is described as changes in gene expression,
which do not involve alterations in the DNA sequence [1].
Such changes include DNA methylation, histone modifi-
cations and involve chromatin modifications. DNA
methylation is one of the best characterized chromatin
modifications and the human genome is predominantly
methylated on CpG motifs. Most of the CpGs are clustered
together (CpG islands). They are enriched in promoters,
where their methylation results in gene silencing.
However, the promoter methylation level is usually low
and tissue-specific methylation is primarily found at the
shores of CpG islands [2]. Interestingly, methylation
within the body of genes usually marks active transcrip-
Correspondence: Tammaryn Lashley, Research Fellow, Queen Square
Brain Bank, Department of Molecular Neuroscience, UCL Institute of
Neurology, Queen Square, London WC1N 3BG, UK. Tel: +44 207 679
4023; Fax: +44 207 676 2062; E-mail: T.Lashley@ion.ucl.ac.uk
1Joint first authors.
497© 2014 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution
and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Neuropathology and Applied Neurobiology (2015), 41, 497–506 doi: 10.1111/nan.12183
tion [3]. DNA methylation is mediated by DNA methyl
transferases (DNMT), whereas the recently discovered
5-hydoxymethyl deoxycytosine (5hmC) in DNA paved the
way for the elucidation of the elusive 5mC demethylation
pathway. The current view is that 5mC is oxidized by ten
eleven translocation (TET) enzymes via 5hmC to 5-formyl-
and 5-carboxylcytosine that are excised by a glycosidase
and base-excision repair introduces a cytosine to fill the
gap (for review Song and He [4]). In addition to being an
intermediate in demethylation, 5hmC and probably the
further oxidation products also have a regulatory role,
5hmC marking gene activation. Epigenetic changes
including DNA methylation/demethylation do take place
during the life time, marking the influence of environ-
mental factors on gene expression, thus they may mediate
at the molecular level the effects of life events on disease
risk and provide a potential explanation for disease dis-
cordance despite genetic similarities [5].
Compared with some other fields (e.g. cancer),
epigenetic mechanisms have been studied less in Alzhei-
mer’s disease (AD), the most prevalent neurodegenerative
disease, although there is now growing interest in such
mechanisms [6]. The characteristic features of AD (cogni-
tive impairment and neuropathological changes) are
similar in the early-onset and the late-onset forms of the
disease. Both forms of AD have genetic components.
Although mutations in three genes (amyloid precursor
protein (APP), presenilin-1, and presenilin-2), identified
in the early-onset familial form, account for only less than
2% of the cases, they have established the central role of
amyloid in the pathogenesis of AD [7]. Large scale
genome-wide association studies (GWAS) have confirmed
the role of ApoE as the most important genetic risk factor
for late onset AD. In addition, they have also identified
normal variants of further genes (CLU, PICALM, BIN1,
CR1, ABCA7, MS4A, EPHA1, CD33, CD2AP), which are
associated with increased disease risk [8]. Most recently
TREM2 variants with large effects have been recognized
[9,10]. However, because these risk factors are neither
necessary nor sufficient for the development of late onset
AD, other factors including epigenetic modifications are
likely to play a role in the pathogenesis.
Interest in epigenetic changes in AD is currently
increasing. Hitherto, most studies analysed DNA
methylation in the brains of AD cases. Earlier studies
examined DNA methylation in a few AD candidate genes
and genes related to growth and development of the CNS
and detected slight changes, if at all, compared with
control brains [11–14]. The study by Bakulski et al. was
the first to provide a semi-unbiased, quantitative, genome-
wide localization of DNA epigenetic differences in the
human frontal cortex between AD cases and controls [15].
Compared with controls, 6% of genes featured on
the arrayed were differentially methylated in the AD
samples, while about the same number of sites being
hypermethylated as hypomethylated. Therefore, in view of
global changes, these studies on site-specific DNA
methylation showed rather modest alterations in AD com-
pared with controls.
In contrast, Mastroeni et al. using immunocytochemis-
try reported a very severe reduction of this epigeneteic
mark in AD entorhinal cortex [16] and the temporal cortex
[17], while nuclear staining was similar to controls in the
cerebellum that is relatively unaffected by AD pathology.
These studies have been extended recently and a similar,
although less severe, reduction in immunocytochemically
detectable DNA methylation in the AD hippocampus was
reported [18]. However, other studies have reported global
DNA hypermethylation in various brain regions in AD
cases compared to neurologically normal controls [19–
21], whereas Condliffe et al. [22] found no significant dif-
ference in DNA methylation in the entorhinal cortex
between AD and control cases. In some of these studies
5hmC levels were also determined by ELISA and
immunohistochemically and these results are also contro-
versial, Coppieters et al. reporting increased levels in AD
brain tissue, whereas Chouliaras et al. and Condliffe et al.
[18,22] found decreases.
The discrepancies among these studies prompted us to
screen a cohort of AD cases held at Queen Square Brain
Bank for Neurological Disorders (UCL Institute of Neurol-
ogy) and compare the levels of global DNA methylation
and hydroxymethylation to neurologically normal control
cases, to elucidate whether global DNA methylation is
involved in the pathogenesis of AD.
Material and methods
Cases
The brain samples from AD and neurologically normal
control cases were obtained from Queen Square Brain
Bank (QSBB), UCL Institute of Neurology, London, UK.
Ethical approval for the study was obtained from the
National Hospital for Neurology and Neurosurgery Local
Research Ethics Committee. AD patients fulfilled the clini-
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cal NINCDS criteria for probable AD [23] and met the
neuropathological CERAD criteria for definitive AD [24].
Neurologically normal controls were cases that had died
without history of dementia, psychiatric or neurological
diseases. Detailed patient demographics are given in
Table 1. The study was approved by the tissue request
committee of the QSBB. A total of 12 AD cases and
14 neurologically normal controls (years, control:
75.93 ± 5.24 vs. AD: 68.17 ± 3.1; P = 0.2323) and post
mortem delay (hours, control: 58.90 ± 10.75 vs. AD:
59.42 ± 8.1; P = 0.9701). All AD cases have been geneti-
cally tested and this study included two familial AD cases
carrying a PSEN1 intron 4 mutation (case 24) and an
APP V717L mutation (case 25).
Immunohistochemistry
Seven-micron-thick tissue sections from the entorhinal
cortex and cerebellum were cut from the AD and con-
trol cases. Commercially available anti-methylcytosine
(1:500; Genway, San Diego, CA, USA) and anti-
hydroxmethylcytosine (1:10 000; Active Motiff, Belgium)
antibodies were used in this study. Briefly, immuno-
histochemistry required pressure cooker pre-treatment in
citrate buffer pH6.0. Endogenous peroxidase activity was
blocked with 0.3% H2O2 in methanol and non-specific
binding with 10% dried milk solution. Tissue sections
were incubated with the primary antibodies overnight at
4°C, followed by biotinylated anti-mouse IgG (1:200,
30 min; DAKO) and ABC complex (30 min; DAKO). Colour
was developed with di-aminobenzidine/H2O2 [25]. Dele-
tion of primary antibody or incubation with pre-immune
serum resulted in abolition of specific immunoreactivity
as previously reported [17]. Double immunohistochemi-
cal staining using anti-methylcytosine and GFAP was
carried out to confirm the majority of nuclei stained were
neuronal. Briefly sections were incubated in both primary
antibodies overnight at 4°C followed by incubation with
Alexa Fluor 488 and 565 (1:1000, 2 h) and viewed with
a Leica DM5500B fluorescence microscope using 3D
deconvolution post-processing.
Semiquantification of immunohistochemical
staining and statistical analysis
Semi-quantitative immunohistochemical analysis was
undertaken in both the AD and neurologically normal
control cases. The region of interest was identified by
comparing stained sections with haematoxylin and eosin
(H&E) counterparts, on which a consultant neuro-
pathologist identified the location of the layer 2/3
entorhinal cortex. Criteria were selected to identify
neuronal nuclei and exclude glial nuclei. Using an objective
×40, only nuclei within a neurone with a diameter of
at least 25 μm were counted; as this excluded
oligodendrocytes, astrocytes and microglia, the proce-
dure was considered to analyse neuronal nuclei. The
observer was trained in identification of neuronal nuclei
and distinguishing them from glial cell nuclei, and was
blind to the underlying diagnosis in each case. Using a
dictaphone, the staining intensity of the first 100
neuronal nuclei among the pre-alpha clusters were
recorded. Neuronal nuclei were divided into three levels
on the basis of staining intensity: weak, medium and
strong. Benchmark values for each of these intensities
were established through collective review of stained
specimens and arrival at consensus (Figure S1). To fairly
assess differences in antibody staining between different
cases inter and intra rateability analysis was performed.
In order to establish that our method of discriminating
nuclei based on staining intensity was reliable, and that
our observations were reproducible and consistent, two
observers carried out a preliminary count using six
samples. An intra- and inter class correlation (ICC) vali-
dated this method by showing high concordance and low
variability between observers (intra ICC 0.9713; inter
ICC 0.9696). This method of analysis was undertaken to
avoid bias due to neurone loss that occurs in AD.
Quantification of global DNA methylation
using ELISA
DNA was extracted from 100 mg of entorhinal cortex from
9 AD cases and 8 normal control cases (Table 1), using a
phenol/chloroform extraction method [26]. Briefly frozen
tissue samples were placed in 500 μl extraction buffer (0.5
% SDS, 0.1 M NaCl, 20 mM Trizma base, 25 mM EDTA
disodium) along with 50 μl proteinase K (10 mg/mL).
Samples were incubated at 55°C for 12 h, removed from
the water bath and 0.8 mL PCI (phenol : chloro-
form : isoamyl alcohol; Sigma, Dorset, UK) added. The
aqueous layer was removed from each sample and 50 μl of
3 M Na-acetate was added together with 1 mL 100%
ethanol. The samples were kept at −20°C for 2 h, spun at
12 000 rpm and the aqueous supernatant removed.
The pellets were washed in ethanol and allowed to
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dry. Pellets were suspended in Tris-EDTA buffer and con-
centration and quality determined using an Eppendorf
spectrophotometer.
The 5mC and 5hmC content of the extracted DNA were
measured by a methylated and hydroxymethylated DNA
quantification kit (Epigentek, NewYork, USA). Briefly, wells
were coated with 200 ng of DNA (each case was tested in
duplicate). The methylated and hydroxymethylated frac-
tion of DNA was detected using the respective capture and
detection antibodies and quantified colorimetrically by
reading the absorbance at 450 nm in a microplate reader.
The results were expressed as units calculated according to
the manufacturer’s manual (5mC or 5hmC as a percentage
of DNA). Multiple ELISAs were carried out on the same
samples and an interclass correlation (ICC) validated this
method by showing high concordance and low variability
between different ELISA runs (inter ICC 0.8073).
Statistical analysis
Statistical analysis was performed using Graphpad Prism
5 software (GraphPad Software Inc., CA, USA). Continu-
ous variables were analysed using either a two-tailed t-test
or a Mann–Whitney U-test as appropriate, while continu-
ous variables between several groups were compared
using the Kruskal–Wallis test. The statistical significance
level was established at P ≤ 0.05.
Results
Global DNA methylation and
hydroxymethyation immunoreactivity
For the immunohistochemical analysis of 5mC and 5hmC
we examined 6 AD and 6 neurologically normal control
cases from the cohort listed in Table 1 [age at death
(years) − control: 61.00 ± 8.15 vs. AD: 61.00 ± 2.22
(P = 1.00)] and post mortem delay [(hours), control:
45.65 ± 10.68 vs. AD: 49.83 ± 11.56 (P = 0.7957)].
Using either the 5mC or 5hmC antibody, staining intensity
of the neuronal nuclei showed variation that was evident
in both the control and AD cases (Fig. 1 and Figures S1
and S2). 5mC and 5hmC immunohistochemistry staining
of the cerebellum, a region relatively unaffected in AD,
Figure 1. 5-methylcytosine immunohistochemistry in an AD (case 18) and a normal control (case 1). (A) 5-methylcytosine
immunohistochemistry in the entorhinal cortex (stars) demonstrates the amount of staining seen at three magnifications [×2 (A), ×10 (B)
and ×40 (C)]. (D) Staining intensity in AD and control cerebellum (×10). Similar staining patterns were observed between the AD cases and
normal controls.
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showed comparable staining patterns in both the neuro-
logically normal controls and AD cases (Fig. 1D). The vari-
ation in staining intensity was evident in all cell types and
all neuronal and all glial nuclei were labelled, as no nuclei
were observed which contained only the haematoxylin
counterstain.
Semi-quantification of global DNA methylation
and hydroxymethylation immunohistochemistry
In order to obtain semi-quantitative data for analysis, we
divided the different degrees of staining intensity of
nuclei into three categories: weak, medium and strong
(Figure S1). Neuronal nuclei were distinguished from glial
nuclei by virtue of their larger size. This was also clarified
using double immunohistochemical staining with GFAP
(Figure S3). Based on the staining intensity, one hundred
neuronal nuclei from the entorhinal cortex were assessed.
No significant differences were detected between the AD
and control cases in the degree of either the 5mC- or 5hmC-
labelled neuronal nuclei (5mC strong, P = 0.7525;
medium, P = 0.5271; weak, P = 0.5625; 5hmC strong,
P = 0.2575; medium, P = 0.4649; weak, P = 0.6863)
(Fig. 2).
Quantification of 5mC and 5hmC levels using
enzyme-linked immunosorbent assay (ELISA)
Cases used for the ELISA are listed in Table 1 [age at death
(years), control: 81.67 ± 6.25 vs. AD: 71.56 ± 3.17
(P = 0.1683)] and post mortem delay [hours, control:
70.11 ± 14.86 vs. AD: 57.07 ± 9.65 (P = 0.4723)]. The
quantification of the amount of 5mC and 5hmC showed
no significant difference between the control and AD cases
(P = 0.9960 and 0.6090 respectively) (Fig. 3). To assess
whether underlying pathological lesions had an impact on
DNA methylation, we reanalysed the data after dividing
our cohort into three groups: (1) neurologically normal
controls with no pathology (Braak and Braak stage 0), (2)
neurologically normal controls with underlying Aβ and
tau pathology (Braak and Braak stage 1–3) (‘preclinical
AD’; CERAD scores and Braak and Braak staging listed in
Table 1), (3) cases in which both the clinical symptoms
and pathology fulfilled AD criteria (Braak and Braak stage
4–5). No significant difference in the amount of 5mC
(P = 0.9045) and 5hmC (P = 0.8255) where seen when
the cases were split according to the underlying pathology
(Fig. 4).
Figure 2. Semi-quantitative analysis of global 5-methylcytosine (A, 5mC) and 5-hydroxymethylcytosine (B, 5hmC) immunohistochemistry
in AD and normal controls. No significant difference were detected in numbers of strong, medium and weakly stained neuronal nuclei
counted in the entorhinal cortex from AD vs. normal control cases.
Figure 3. Levels of 5-methycytosine (5mC) and 5-
hydroxymethylcytosine (5hmC) in AD and normal controls (NC).
Amounts of 5mC and 5hmC were measured in the entorhinal
cortex using ELISA in AD and normal controls. No statistical
significance was found between the two groups.
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Correlation analysis between 5mC and
5hmC levels
According to the current model, 5hmC is derived from
5mC by TET-mediated oxidation [4]. Consistent with this,
there was a positive, significant correlation between levels
of 5mC and 5hmC in the AD cohort (Pearson correlation
test: r = 0.7528; P = 0.0192), while the trend was also
positive in the normal control cases, but this was not sig-
nificant (r = 0.6192; P = 0.1017) (Fig. 5).
Correlation between levels of 5mC/5hmC and
other case variables
Pearson correlation tests were used to determine whether
any of the case variables had an effect on the levels of 5mC
or 5hmC. No significant correlation was found between
the levels of 5mC or 5hmC and the age at death, Braak and
Braak tau stages, and total Aβ plaque load (Table S1).
Discussion
Global DNA methylation was determined in the present
work in the entorhinal cortex of AD cases and controls
using immunohistochemistry with 5mC antibody. The
staining was primarily in nuclei and every nucleus was
labelled. We counted only nuclei the diameter of which
was at least 25 μm, and these were considered as
neuronal. This analysis eliminated the bias that could be
due to neurone cell loss in AD. Differences were observed
in the staining intensity; therefore, we adopted a semi-
quantitative approach in order to generate data we could
test for statistical significance, dividing stained neuronal
nuclei into three categories of intensity (weak, medium,
strong). No significant difference was observed between
the degree of labelling between AD and control cases in
the cohort of cases used in this study.
We also determined global DNA methylation using an
enzyme-linked immunosorbent assay and observed no sig-
nificant differences between AD and control cases. The
neuropathological examination showed that some of the
clinically normal cases had AD associated pathology,
amyloid plaques and neurofibrillary tangles in the brain
(defined here as ‘preclinical AD’). These cases were sepa-
rated from the control group and the data were reanalysed
comparing the clinically and pathologically normal
control group with both the ‘preclinical’ and the patent
AD cohorts. No significant difference was detected in com-
parison with control, in contrast to the report by Bradley-
Whitman and Lovell et al., which showed increased DNA
methylation not only in late onset AD, but also in the
preclinical subset of cases [20].
Figure 4. Levels of 5-methycytosine (5mC) and 5-
hydroxymethylcytosine (5hmC) in AD, pre-clinical (PC; clinically
normal, but AD-related pathology displaying group) and
cognitively normal (CN, no AD-related pathology) cases. Levels of
5mC and 5hmC were measured using ELISA. Kruskal–Wallis test
showed no statistical significance among the three groups.
Figure 5. Pearson correlation analysis between 5-methycytosine (5mC) and 5-hydroxymethylcytosine (5hmC) levels in the entorhinal
cortex in AD (A) and normal control cases (B). Levels of 5mC and 5hmC were significantly correlated in the AD cases. Although there was a
trend in the normal controls this was not significant (P = 0.1017).
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Demethylation of 5mC in DNA is mediated by TET-
catalysed oxidation to 5hmC that, in addition of being an
intermediate in the demethylation pathway, has also regu-
latory functions [4]. Immunohistochemical detection of
5hmC showed, similar observations to the 5mC labelling,
that all nuclei were stained and no significant differences
were detected between the labelling intensity of AD and
control cases. This observation was confirmed by deter-
mining 5hmC content using ELISA, which also showed no
significant differences between AD and control cases.
There was significant correlation between 5mC and 5hmC
levels in the AD group and a positive, although no signifi-
cant trend was observed in the control group. These obser-
vations are consistent with the findings of Chouliaras
et al. and Coppieters et al. [18,21].
Using Pearson correlation analysis, we observed no sig-
nificant effects between DNA modifications and case vari-
ables (age, Braak and Braak tau staging and total Aβ
levels). This is in agreement with the observations of
Coppieters et al., who also found that the relation between
DNA modifications and post mortem delay is not signifi-
cant [21]. It has, however, been reported that 5mC and
5hmC levels increase with age [18,27]. As the major
increase in 5mC levels occurs between early development
and about 60 years [27] and our samples with the excep-
tion of a few were relatively old (see Table 1), this might
explain the absence of correlation with age [21].
Our observation that global DNA methylation is not sig-
nificantly different in the entorhinal cortex of AD cases
from controls is consistent with the finding of Condliffe
et al. [22]. Further, genome site-specific analysis of DNA
methylation has failed to identify marked alterations in the
AD brain. Earlier studies, examining DNA methylation of
a few AD candidate genes detected slight changes, if at all,
compared to control brains [11–13]. In a quantitative,
genome-wide localization of DNA methylation differences
in the human frontal cortex between AD cases and
control, Bakulski et al. found bidirectional changes
with about the same number of hypermethylation as
hypomethylation sites [15].
In contrast, Mastroeni et al. used 5mC immunocyto-
chemistry and reported a very severe reduction of this
epigenetic mark in the AD entorhinal cortex [16,17].
These studies have been extended recently and a reduction
in immunocytochemically detected DNA methylation in
the AD hippocampus was reported [18]. A decrease
in 5hmC levels in the AD hippocampus was also reported in
this work, which was also found by Condliffe et al., who also
detected reduced 5hmC levels in the cerebellum that is
relatively unaffected in AD [22]. However, other observa-
tions show an increase in global DNA methylation in the
AD brain and some of these studies also found an increase
in the level of 5hmC in the AD brain [19–21] (Table S2).
The reason for the differences in the reported DNA
methylation in AD is not clear. Different brain regions
were studied in the various works and there is evidence
that methylated/hydroxymethylated DNA levels vary
among brain regions [28–30]. However, some of the find-
ings by the different groups are contradictory even for the
same region. There have also been differences in the tissue
processing and immunostaining procedures. Further, the
sample size in many of these studies, including our own,
was relatively small.
The limitation of the global DNA methylation approach
should be kept in mind. Site-specific differential DNA
methylation has been already shown in AD and might
have an important bearing on disease pathology. Due to
the heterogeneous cellular composition of the brain, cell-
type specific investigations are of paramount importance.
Further studies are needed in which use is made of
current technologies, including genome-wide analysis of
specific cell types, to appreciate the involvement of DNA
methylation in AD pathology.
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Supporting information
Additional Supporting Information may be found in the
online version of this article at the publisher’s web-site:
Figure S1. 5-methylcytosine immunohistochemical
staining demonstrating the three levels of neuronal nuclei
staining intensity; weak, medium and strong. Benchmark
values for each of these intensities were established
through collective review of stained specimens and arrival
at consensus.
Figure S2. 5-hydroxymethylcytosine immunohisto-
chemistry in an AD (case 18) and normal control (case 1).
Demonstrating 5hmC staining in the entorhinal cortex of
AD cases and normal controls.
Figure S3. 5-Methylcytosine (green) and GFAP (red)
double immunohistochemical staining in the entorhinal
cortex. The majority of nuclei stained with the
5-methylcytosine antibody are not labelled with GFAP
antibody. Arrows show astrocytes that are both
methylcytosine and GFAP positive. Higher magnification
is shown in the inserts.
Table S1. Pearson correlation analysis to determine
whether case variables correlated with the levels of 5mC
and 5hmC as measured by ELISA. No significance was
found between age at death, Braak and Braak tau staging
and Aβ load in comparison with either 5mC and 5hmC
levels.
Table S2. Summary of recent findings on DNA
methylation in the brain in AD. *In AD cases accelerated
ageing-related changes in 2 genes from 50 determined; **
Age-dependent epigenetic drift is more pronounced in AD
than in control cases. IHC, immunohistochemistry.
hypermethylation in AD; hypomethylation in AD; ‘0’ no
significant difference between controls and AD cases.
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